<unk> , aliases including<unk>  sodium, OGX-011, and CC-8490, is an investigational drug that was under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer,<unk>  showed no benefit in improving over all survival.<unk>  was developed through a collaboration of OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd agreed to develop and commercialise<unk> .
Custirsen
Truenat
Epiestriol
Bolesatine
Sesquimustard
Esthiomene
Phenibut
Penmesterol